Individual prognosis of occurrence or progression of and/or for individual diagnosis of neuropathy of mammal, comprises detecting expression of mRNA of a gene in a tissue- or fluid sample of mammal, where the gene is e.g. adiponectin

摘要

Individual prognosis of the occurrence or the progression of and/or for individual diagnosis of a neuropathy of a mammal, comprises detecting the expression of mRNA of at least a gene in a tissue- or fluid sample of the mammal, where the gene is selected, (a) for the individual prognosis of the occurrence or progression of neuropathy of the mammal, from e.g. adiponectin (ADIPOQ), lipoprotein lipase (LPL), or peroxisome proliferator activated receptor-gamma (PPARG), and (b) for individual diagnosis of neuropathy of the mammal, from PPARG or nicotinamide nucleotide transhydrogenase (NNT). Individual prognosis of the occurrence or the progression of and/or for individual diagnosis of a neuropathy of a mammal, comprises detecting the expression of mRNA of at least a gene in a tissue- or fluid sample of the mammal, where the gene is selected, (a) for the individual prognosis of the occurrence or progression of neuropathy of the mammal, from adiponectin (ADIPOQ), lipoprotein lipase (LPL), peroxisome proliferator activated receptor-gamma (PPARG), thyroid hormone responsive protein (THRSP), carbonic anhydrase-3 (CAR3), insulin-like growth factor binding protein-5 (IGFBP5), neurofilament light chain (NEFL), neurofilament medium (NEFM), claudin-1 (CLDN1), stearoyl-coenzyme A desaturase-1 (SCD1), cysteine dioxygenase-1 (CDO1), glial cell derived neurotrophic factor (GDNF), retinol binding protein-4 (RBP4), nexilin (NEXN), early B-cell factor-1 (EBF1), interleukin-1 receptor 1 (IL1R1), periaxin (PRX), ribosomal RNA promotor binding protein (RIBIN), steroid sensitive gene-1 (SSG1), transforming growth factor beta 3 (TGFB3), chemokine C-X-C motif ligand 12 (CXCL12), peripheral myelin protein 22 kDa (PMP22), inhibitor of DNA binding 3 (ID3), or glutathione-S-transferase, pi 2 (GSTP2), and (b) for individual diagnosis of neuropathy of the mammal, from PPARG, CAR3, nicotinamide nucleotide transhydrogenase (NNT), insulin-like growth factor-1 (IGF1), IGFBP5, dermatopontin (DPT), D-dopachrome tautomerase (DDT), interleukin-16 (IL16), RIBIN, SSG1, glutathione-S-transferase theta 2 (GSTT2), cathepsin A (CTSA), fructosamine-3-kinase related protein (FN3KRP), small proline-rich repeat protein 1A (SPRR1A), THRSP, protein kinase, cyclic adenosine monophosphate dependent regulatory, type II beta (PRKAR2B), GSTP2, RBP4, TGFB3, myosin light chain v2 (MYL1V2), CXCL12, EBF1, IL1R1, PRX, phosphodiesterase-2A (PDE2A), phosphodiesterase 3B (PDE3B), or ID3. An independent claim is included for prognostic markers or disease markers for the occurrence of neuropathy, where the prognostic markers are mentioned in (a) and (b).